KEY POINTS
- This prospective, single-center, nonrandomized phase II trial (NCT02473536) evaluated neoadjuvant stereotactic ablative radiotherapy (SABR) targeting inferior vena cava (IVC) tumor thrombus before radical nephrectomy and thrombectomy in renal cell carcinoma. Between July 2015 and January 2024, 23 patients received SABR, 22 underwent surgery, and 21 were included in the primary efficacy analysis. Eligible patients had Mayo level II–IV IVC tumor thrombus, and three patients had previously treated or limited metastatic disease.
- Neoadjuvant SABR targeted radiographically identified IVC tumor thrombus using 40 Gy in five fractions or 36 Gy in three fractions, with definitive surgery performed 4–14 days after irradiation. In the primary analysis cohort, 12 patients (57%) received 40 Gy/5 and nine (43%) received 36 Gy/3. Most had clear-cell RCC (19/21; 90%), all tumors were grade 3 or 4, and nine patients (43%) had Mayo level III–IV thrombus at baseline.
- The primary endpoint was one-year recurrence-free survival (RFS) compared with a prespecified historical surgery-alone benchmark of 55.7%. Observed one-year RFS was 71.4% (80% CI 56.6–82.0%; 95% CI 47.2–86.0%), an absolute numerical difference of 15.7 percentage points. The trial met its predefined phase II screening criterion using α=0.20 (p=0.09), but this does not represent conventional statistical proof of superiority over surgery alone.
- At a median reported follow-up of 108.6 months, median RFS was 13.7 months, while median overall survival was 49.8 months and median cancer-specific survival 80.9 months. One-year overall and cancer-specific survival were both 95.2%. In an exploratory analysis restricted to 18 patients without metastatic disease, one-year RFS was 66.7%, highlighting uncertainty around the magnitude and generalizability of the apparent survival signal.
- Neoadjuvant treatment did not prevent surgical completion in most patients, and no 90-day perioperative deaths, pulmonary emboli, or acute thrombus-related complications were reported. However, perioperative morbidity remained substantial: 12/21 patients (57%) experienced grade ≥3 perioperative adverse events. Across the complete 23-patient safety cohort, four grade 4 surgery-attributed events occurred, while four grade 3 and no grade 4–5 radiation-attributed events were reported. Thus, feasibility should not be confused with absence of serious treatment-related morbidity.
- Recurrence and progression remained predominantly distant, particularly pulmonary, with only one local recurrence reported. Four patients with radiographically classified Mayo level III thrombus were found to have level II disease during surgery, but the authors explicitly caution that this difference cannot be attributed to SABR because radiological and operative assessments can disagree. Similarly, regression of nonirradiated metastases in two patients cannot establish an abscopal effect.
- Exploratory translational analyses suggested biological activity. The change in Ki-67 proliferation index was lower in irradiated tumor thrombus than in five nonirradiated controls (−2.18% vs +3.90%; p=0.04). Tumor-informed circulating tumor DNA was detected in 16/16 patients with available plasma, and its fraction decreased in 6/7 patients with paired samples. However, the small control and biomarker subsets, lack of a randomized surgery-alone group, and differences from historical comparator populations prevent causal interpretation of these findings.
CLINICAL TAKEAWAY
Neoadjuvant SABR targeting IVC tumor thrombus before nephrectomy and thrombectomy appeared technically feasible without delaying definitive surgery or increasing observed radiation-attributed grade 4–5 toxicity. The encouraging recurrence-free survival signal supports further prospective investigation, but the small nonrandomized cohort, considerable perioperative morbidity, and reliance on historical controls mean that an oncological benefit over surgery alone has not been established.